New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2013
07:32 EDTHZNPHorizon Pharma gets U.K. marketing authorization for DUEXIS
Horizon Pharma announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted marketing authorization for DUEXIS for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen administered three times a day and who are at risk of developing non-steroidal anti-inflammatory drug associated gastric and/or duodenal ulcers. Horizon is seeking to license rights to DUEXIS in Europe to one or more commercial partners.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
16:12 EDTHZNPHorizon Pharma reports positive effect of RAYOS in reducing joint stiffness
Subscribe for More Information
November 14, 2014
08:06 EDTHZNPHorizon Pharma 11.66M share Secondary priced at $12.05
Subscribe for More Information
November 13, 2014
14:56 EDTHZNPHorizon Pharma says Watson Labs filed ANDA for generic PENNSAID
Subscribe for More Information
07:06 EDTHZNPHorizon Pharma files to sell 11.66M shares for existing holders
Horizon Pharma announced a proposed underwritten secondary offering of 11.66M of its ordinary shares held by certain of its existing shareholders. Morgan Stanley, Citigroup, Cowen and Jefferies are acting as joint book-running managers for this offering. JMP Securities is acting as financial advisor for this offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use